Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung

计划入组 25 人 · 首次发布于 2013 年 6 月 13 日

RET Inhibitor Rechallenge Shows Promise in Pre-Treated NSCLC Patients After Toxicity-Related Discontinuation

Final ARROW Study Data Shows Pralsetinib Achieves 70% Response Rate in RET+ NSCLC with Durable Survival Outcomes

SY-5007 Demonstrates Promising Efficacy in RET-Altered Solid Tumors: Phase 1 Trial Results